Cancer Gene Therapy Market by Therapy (Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer) - Global Opportunity Analysis and Industry Forecast, 2017-2023

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION

1.2. KEY BENEFITS

1.3. KEY MARKET SEGMENTS

1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE

3.2. KEY FINDINGS

3.2.1. Top investment pockets

3.2.2. Top winning strategies

3.3. REGULATION AND REIMBURSEMENT SCENARIO

3.4. PORTERS FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS

3.4.2. Drivers

3.4.3. Restraints

3.4.4. Opportunities

CHAPTER 4 CANCER GENE THERAPY MARKET, BY THERAPY

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. ONCOLYTIC VIROTHERAPY

4.2.1. Key market trends

4.2.2. Growth factors and opportunities

4.2.3. Market size and forecast

4.2.4. Adenovirus

4.2.5. Lentivirus

4.2.6. Retro virus

4.2.7. Adeno associated virus

4.2.8. Herpes simplex virus

4.2.9. Alpha Virus

4.2.10. Vaccinia Virus

4.2.11. Simian Virus

4.2.12. Others

4.3. GENE TRANSFER

4.3.1. Key market trends

4.3.2. Growth factors and opportunities

4.3.3. Market size and forecast

4.3.4. Naked plasmid vector

4.3.5. Electroporation

4.3.6. Sonoportion

4.3.7. Magnetofection

4.3.8. Gene Gun

4.4. GENE-INDUCED IMMUNOTHERAPY

4.4.1. Key market trends

4.4.2. Growth factors and opportunities

4.4.3. Market size and forecast

4.4.4. Delivery of cytokines gene

4.4.5. Delivery of tumor antigen gene

CHAPTER 5 CANCER GENE THERAPY MARKET, BY GEOGRAPHY

5.1. OVERVIEW

5.2. NORTH AMERICA

5.2.1. Key market trends

5.2.2. Key growth factors and opportunities

5.2.3. Market size and forecast

5.2.3.1. U.S. market size and forecast

5.2.3.2. Canada market size and forecast

5.2.3.3. Mexico market size and forecast

5.2.4. North America Cancer gene therapy Market by Therapy

5.3. EUROPE

5.3.1. Key market trends

5.3.2. Key growth factors and opportunities

5.3.3. Market size and forecast

5.3.3.1. Germany market size and forecast

5.3.3.2. France market size and forecast

5.3.3.3. UK market size and forecast

5.3.3.4. Italy market size and forecast

5.3.3.5. Spain market size and forecast

5.3.3.6. Rest of Europe market size and forecast

5.3.4. Europe Cancer gene therapy Market by Therapy

5.4. ASIA-PACIFIC

5.4.1. Key market trends

5.4.2. Key growth factors and opportunities

5.4.3. Market size and forecast

5.4.3.1. Japan market size and forecast

5.4.3.2. China market size and forecast

5.4.3.3. Australia market size and forecast

5.4.3.4. India market size and forecast

5.4.3.5. South Korea market size and forecast

5.4.3.6. Taiwan market size and forecast

5.4.3.7. Rest of Asia-Pacific market size and forecast

5.4.4. Asia-Pacific Cancer gene therapy Market by Therapy

5.5. LAMEA

5.5.1. Key market trends

5.5.2. Key growth factors and opportunities

5.5.3. Market size and forecast

5.5.3.1. Brazil market size and forecast

5.5.3.2. Turkey market size and forecast

5.5.3.3. Saudi Arabia market size and forecast

5.5.3.4. South Africa market size and forecast

5.5.3.5. Rest of LAMEA market size and forecast

5.5.4. LAMEA Cancer gene therapy Market by Therapy

CHAPTER 6 COMPANY PROFILES

6.1. ADAPTIMMUNE

6.1.1. Operating business segments

6.1.2. Business performance

6.1.3. Key strategic moves and developments

6.2. GLAXOSMITHKLINE

6.2.1. Operating business segments

6.2.2. Business performance

6.2.3. Key strategic moves and developments

6.3. BLUEBIRD BIO, INC.

6.3.1. Operating business segments

6.3.2. Business performance

6.3.3. Key strategic moves and developments

6.4. MERCK

6.4.1. Operating business segments

6.4.2. Business performance

6.4.3. Key strategic moves and developments

6.5. CELGENE

6.5.1. Operating business segments

6.5.2. Business performance

6.5.3. Key strategic moves and developments

6.6. SHANGHAI SUNWAY BIOTECH

6.6.1. Operating business segments

6.6.2. Business performance

6.6.3. Key strategic moves and developments

6.7. BIOCANCELL

6.7.1. Operating business segments

6.7.2. Business performance

6.7.3. Key strategic moves and developments

6.8. SHENZHEN SIBIONO GENETECH

6.8.1. Operating business segments

6.8.2. Business performance

6.8.3. Key strategic moves and developments

6.9. SYNERGENE THERAPEUTICS

6.9.1. Operating business segments

6.9.2. Business performance

6.9.3. Key strategic moves and developments

6.10. ONCOGENEX PHARMACEUTICALS

6.10.1. Operating business segments

6.10.2. Business performance

6.10.3. Key strategic moves and developments

LIST OF TABLES

TABLE 1. GLOBAL CANCER GENE THERAPY MARKET, BY THERAPY, 2016-2023 ($MILLION)

TABLE 2. CANCER GENE THERAPY MARKET FOR GENE INDUCED IMMUNOTHERAPY, BY REGION, 2016-2023 ($MILLION)

TABLE 3. CANCER GENE THERAPY MARKET FOR ONCOLYTIC VIROTHERAPY, BY REGION, 2016-2023 ($MILLION)

TABLE 4. CANCER GENE THERAPY MARKET FOR GENE TRANSFER, BY REGION, 2016-2023 ($MILLION)

TABLE 5. CANCER GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)

TABLE 6. NORTH AMERICA CANCER GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)

TABLE 7. NORTH AMERICA CANCER GENE THERAPY MARKET, BY THERAPY, 2016-2023 ($MILLION)

TABLE 8. EUROPE CANCER GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)

TABLE 9. EUROPE CANCER GENE THERAPY MARKET, BY THERAPY, 2016-2023 ($MILLION)

TABLE 10. ASIA-PACIFIC CANCER GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)

TABLE 11. ASIA-PACIFIC CANCER GENE THERAPY MARKET, BY THERAPY, 2016-2023 ($MILLION)

TABLE 12. LAMEA CANCER GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)

TABLE 13. LAMEA CANCER GENE THERAPY MARKET, BY THERAPY, 2016-2023 ($MILLION)

TABLE 14. ADAPTIMMUNE: COMPANY SNAPSHOT

TABLE 15. ADAPTIMMUNE: OPERATING SEGMENTS

TABLE 16. GLAXOSMITHKLINE: COMPANY SNAPSHOT

TABLE 17. GLAXOSMITHKLINE: OPERATING SEGMENTS

TABLE 18. BLUEBIRD: COMPANY SNAPSHOT

TABLE 19. BLUEBIRD: OPERATING SEGMENTS

TABLE 20. MERCK: COMPANY SNAPSHOT

TABLE 21. MERCK: OPERATING SEGMENTS

TABLE 22. CELGENE: COMPANY SNAPSHOT

TABLE 23. CELGENE: OPERATING SEGMENTS

TABLE 24. SHANGHAI SUNWAY BIOTECH: COMPANY SNAPSHOT

TABLE 25. SHANGHAI SUNWAY BIOTECH: OPERATING SEGMENTS

TABLE 26. BIOCANCELL: COMPANY SNAPSHOT

TABLE 27. BIOCANCELL: OPERATING SEGMENTS

TABLE 28. SHENZHEN SIBIONO GENETECH: COMPANY SNAPSHOT

TABLE 29. SHENZHEN SIBIONO GENETECH: OPERATING SEGMENTS

TABLE 30. SYNERGENE THERAPEUTICS: COMPANY SNAPSHOT

TABLE 31. SYNERGENE THERAPEUTICS: OPERATING SEGMENTS

TABLE 32. ONCOGENEX PHARMACEUTICALS: COMPANY SNAPSHOT

TABLE 33. ONCOGENEX PHARMACEUTICALS: OPERATING SEGMENTS

LIST OF FIGURES

FIGURE 1. SEGMENTATION OF GLOBAL CANCER GENE THERAPY MARKET

FIGURE 2. TOP INVESTMENT POCKETS IN GLOBAL CANCER GENE THERAPY MARKET 2016

FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)

FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE (2014-2016)

FIGURE 5. TOP WINNING STRATEGIES: NATURE AND COMPANY (2014-2016)

FIGURE 6. BARGAINING POWER OF BUYERS

FIGURE 7. BARGAINING POWER OF SUPPLIERS

FIGURE 8. THREAT OF NEW ENTRANTS

FIGURE 9. THREAT OF SUBSTITUTION

FIGURE 10. COMPETITIVE RIVALRY

FIGURE 11. RESTRAINTS AND DRIVERS: GLOBAL CANCER GENE THERAPY MARKET

FIGURE 12. GLOBAL CANCER GENE THERAPY MARKET: SEGMENTATION BY TYPE

FIGURE 13. U.S. CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)

FIGURE 14. MEXICO CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)

FIGURE 15. CANADA CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)

FIGURE 16. UK CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)

FIGURE 17. FRANCE CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)

FIGURE 18. GERMANY CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)

FIGURE 19. REST OF EUROPE CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)

FIGURE 20. INDIA CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)

FIGURE 21. JAPAN CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)

FIGURE 22. CHINA CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)

FIGURE 23. REST OF ASIA-PACIFIC CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)

FIGURE 24. BRAZIL CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)

FIGURE 25. SOUTH AFRICA CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)

FIGURE 26. SAUDI ARABIA CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)

FIGURE 27. REST OF LAMEA CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)